Want to join the conversation?
$PFE's 3Q15 reported revenues reflects YoverY operational growth of 6% mainly driven by the strong performance in developed markets from Prevnar 13 adult, Ibrance and Eliquis as well as from Lyrica primarily in the U.S., one month of legacy Hospira in US and 5% operational growth in emerging markets mainly from Innovative Products.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?